 |
|
|
|
|
| |
|
- Valeant signs licensing agreement for Canadian rights to (C)Xyrem® from Jazz Pharmaceuticals
- Valeant acquires rights to nabilone in the United Kingdom and Europe.
- Valeant files IND for Cesamet® in cancer chemotherapy-induced neuropathic pain.
- Valeant initiates taribavirin Phase 2b clinical study
- Retigabine Phase 2 data published in the peer-reviewed journal, NEUROLOGY
- Courteney Cox signs contract for third year as Kinerase® spokesperson
- Peter J. Blott appointed as Chief Financial Officer
- Valeant initiates partial responder study for Infergen
- Norma A. Provencio and G. Mason Morfit elected to Board of Directors
- Valeant initiates study of retigabine for pain associated with post-herpetic neuralgia
- Valeant completes restructuring with the sale of manufacturing plants in Basel, Switzerland and Humacao, Puerto Rico
- Valeant announces share repurchase program
-
Valeant settles suit with Kali Laboratories on Diastat generic challenge
- Valeant selects next-generation potassium-channel openers for pre-clinical development
- Valeant launches Bedoyecta in the United States
- Valeant announces full enrollment of first retigabine Phase 3 epilepsy study
- Valeant to partner with ASCEND Therapeutics to promote Migranal® to OB/GYNs
- Valeant completes enrollment of second pivotal Phase 3 Trial for epilepsy drug retigabine
- Valeant starts Phase 2 retigabine study for treatment of post-herpetic neuralgia
- Valeant sells Hepatitis-C drug Infergen® to Three Rivers Pharmaceuticals®, LLC
|
|
|
|
